At this year’s EBMT Congress in Florence, Prof. Gandhi Damaj (Hematology Institute, Normandy University, France) presented the latest recommendations from the EBMT Practice Harmonisation and Guidelines Committee on allogeneic hematopoietic cell transplantation (allo-HCT) in PTCL.
The session emphasized the curative role of allo-HCT in PTCL, particularly for relapsed or refractory patients, where retrospective data show significantly improved survival when allo-SCT is used during salvage. This collaborative work brought together insights from 29 experts, focusing on PTCL treatment strategy and transplant modalities.
Key highlights include:
- Consolidation with allo-HCT is preferred in most aggressive or rare PTCL subtypes
- Histology subtype should not determine post-transplant decisions
- Reduced-intensity conditioning (RIC) is preferred for its lower toxicity and broader accessibility
- No current evidence supports routine post-transplant interventions such as MRD monitoring or prophylactic DLI
- Pre-transplant donor selection should follow the sequence: MSD > MUD > haplo/MMUD
From AITL to hepatosplenic and ENKTL subtypes, these recommendations aim to guide transplant decision-making and improve patient outcomes.
Many thanks to Prof. Damaj and colleagues for their leadership in this important harmonization effort.
